Summary
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The company’s product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Partnerships 12
Bristol-Myers Squibb Enters into Agreement with Infinity Pharma 12
Pharm-Olam International Enters into Agreement with Infinity Pharma 13
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
Licensing Agreements 15
PellePharm Enters into Licensing Agreement with Infinity Pharma 15
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 16
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 17
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 18
Equity Offering 19
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 19
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 20
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 22
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 22
Infinity Pharmaceuticals Inc - Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Strategy And Business Planning 28
Jan 11, 2016: Infinity Provides Key 2016 Goals and Financial Guidance 28
Financial Announcements 29
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 29
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 30
Nov 09, 2016: Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results 32
Aug 09, 2016: Infinity Provides Company Update And Reports Second Quarter 2016 Financial Results 34
May 04, 2016: Infinity Provides Company Update And Reports First Quarter 2016 Financial Results 36
Feb 23, 2016: Infinity Provides Company Update and Reports Full-Year 2015 Financial Results 38
Corporate Communications 40
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 40
Jan 04, 2017: Infinity Announces Organizational Changes 41
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Bristol-Myers Squibb Enters into Agreement with Infinity Pharma 12
Pharm-Olam International Enters into Agreement with Infinity Pharma 13
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
PellePharm Enters into Licensing Agreement with Infinity Pharma 15
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 16
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 17
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 18
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 19
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 20
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 22
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 22
Infinity Pharmaceuticals Inc, Key Competitors 25
Infinity Pharmaceuticals Inc, Key Employees 26
Infinity Pharmaceuticals Inc, Subsidiaries 27List of Figures
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
